Who stays? Why succession matters in MedTech M&A

To view this article as originally published on the Today’s Medical Developments Magazie website, click here.

Most owners arrive at a sale process having settled one question: am I staying or am I going? Fair enough. But that’s not what decides whether the deal holds at the valuation you want.

A buyer isn’t primarily buying you. They’re buying a business still running on the Monday after close. So, the conversation that matters is broader than the corner office: which handful of people carry the relationships and the know-how, and will they be there in eighteen months?

If you are staying

Plenty of owners want to keep going, and buyers are often glad to have them. Be clear-eyed about what changes: you’re moving from owner to operator, with a board, a budget, and someone else’s capital allocation discipline. Decisions once made over coffee now have a process attached.

That works when it is discussed honestly in diligence. It goes badly when an owner stays because it smooths the deal, then finds a year later they sold their company and bought themselves a job.

If you are leaving

Then the question is who replaces you, and for most lower-middle-market healthcare companies the honest answer is: several people, partially. Owners here carry the customer relationships, pricing judgment, regulatory history, and supplier goodwill. None of that transfers to one successor; done right, it transfers to a team before the transaction, which strengthens value and eases integration.

When should you start? Now. A general manager who has run the floor for two years reads very differently to a buyer than one promoted three weeks before the teaser goes out. And even if you never sell, the company’s intrinsic value keeps climbing.

Family businesses and second-generation owners

Family ownership adds a layer, because succession has usually been discussed for years and rarely decided. Relationships are personal, the workforce is loyal to a name, customers may have been buying from a family for 30 years. Buyers scrutinize that concentration; they need confidence the brand grows without the family in it. Where the next generation isn’t taking over, say so plainly and early. Buyers handle a clear answer better than a vague one.

The people who actually matter

Usually four to six: the top customer relationships, quality and regulatory, operations, and whoever knows why things are done the way they are. Identify them before a process starts, know what would keep them, and expect the buyer to want them retained.

The strongest position is an owner who says: here’s the team, here’s what they own, here’s why they’re staying. That shows up in the valuation, and in whether the business works after you hand it over.

And don’t do this alone. Sellers who run a proper process with an M&A advisor have been shown to realize more than 20% higher enterprise values than going direct, and an advisor will press you on your team long before a buyer does.


About the authors: Estelle Black is business operations director for Middle Markets for MedTech M&A at MedWorld Advisors. Co-Founder and Managing Director Dave Sheppard is a former medical OEM Fortune 500 executive and an experienced MedTech M&A professional. He can be reached at davesheppard@medworldadvisors.com.

To view this article as originally published on the Today’s Medical Developments Magazie website, click here.

Previous
Previous

When the Medtech Carve-Out Becomes a Competitor

Next
Next

Medtech M&A: choosing between private equity and strategic buyers